GOCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GoHealth Inc (GOCO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits significant financial weakness, negative technical indicators, and lacks positive catalysts. Additionally, analyst sentiment and ratings have turned negative, with price targets being downgraded significantly. There is no evidence of influential trading activity or strong proprietary trading signals to support a buy decision.
The technical indicators for GOCO are bearish. The MACD is negative and expanding downward, the RSI is neutral but trending low at 23.607, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with no signs of reversal. The stock has a low probability of significant short-term gains, with only a 1.48% chance of growth in the next month.
NULL identified. No recent news or events suggest a positive catalyst for the stock.
Analyst downgrades: RBC Capital lowered the price target from $12 to $5, and William Blair downgraded the stock to Market Perform due to weak Q3 results and market headwinds.
Financial performance: Revenue dropped by 71.10% YoY, net income fell by 2950.91% YoY, and EPS decreased by 2665.22% YoY in Q3
Gross margin turned negative at -27.56%, indicating operational inefficiencies.
One large carrier suspended its relationship with the company, further impacting topline performance.
GoHealth's Q3 2025 financial performance was extremely poor. Revenue dropped to $34.18M, down 71.10% YoY. Net income plummeted to -$166.84M, a 2950.91% decline YoY. EPS dropped to -11.8, a 2665.22% decline YoY. Gross margin fell to -27.56%, reflecting significant operational challenges. The company is struggling to generate sustainable positive cash flow and faces market headwinds.
Analyst sentiment is negative. RBC Capital lowered its price target from $12 to $5 and maintained a Sector Perform rating. William Blair downgraded the stock to Market Perform from Outperform, citing weak Q3 results, market headwinds, and uncertainty about the company's ability to generate sustainable cash flow. Analysts are cautious about the company's future performance.
